Stock listing
Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Selected listing: 2563 · HKEX · HKD · HK
Beijing Biostar Pharmaceuticals Co., Ltd. Class H (HKEX:2563), Health Technology. Latest release Dec 15, 2025: Breaking the "Untreatable": Biostar Pharma's…
- Ticker
- HKEX:2563
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- HKEX
- Currency
- HKD
About Beijing Biostar Pharmaceuticals Co., Ltd. Class H
The company specializes in the development and production of pharmaceutical products. Its focus on innovative healthcare solutions positions it within the competitive landscape of the pharmaceutical industry.
Latest news from Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
December 14, 2025
The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer
September 25, 2025
Biostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)
September 15, 2025
All Beijing Biostar Pharmaceuticals Co., Ltd. Class H news →
Research Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co., Ltd. Class H company profile
View the public company page for Beijing Biostar Pharmaceuticals Co., Ltd. Class H on 6ix.
Beijing Biostar Pharmaceuticals Co., Ltd. Class H news
Read company news and market updates connected to Beijing Biostar Pharmaceuticals Co., Ltd. Class H.
Beijing Biostar Pharmaceuticals Co., Ltd. Class H investor events
Find investor webinars, events, and replay context for Beijing Biostar Pharmaceuticals Co., Ltd. Class H.